The management of treatment-experienced HIV patients (including virologic failure and switches)

被引:25
作者
Cutrell, James [3 ]
Jodlowski, Tomasz [4 ]
Bedimo, Roger [1 ,2 ]
机构
[1] VA North Texas Hlth Care Syst, Dept Med, 4500 South Lancaster Rd,111-D, Dallas, TX 75216 USA
[2] Univ Texas Southwestern Med Ctr Dallas, 4500 South Lancaster Rd,111-D, Dallas, TX 75216 USA
[3] Univ Texas Southwestern Med Ctr Dallas, Dept Med, Dallas, TX 75216 USA
[4] VA North Texas Hlth Care Syst, Dept Pharm, Dallas, TX 75216 USA
关键词
adherence; comorbidities; HIV; virologic failure; TENOFOVIR DISOPROXIL FUMARATE; BOOSTED PROTEASE INHIBITOR; LOW-LEVEL VIREMIA; COMBINATION ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE INHIBITORS; HUMAN-IMMUNODEFICIENCY-VIRUS; LOPINAVIR PLUS RALTEGRAVIR; LONG-TERM MORTALITY; T-CELL COUNT; DRUG-RESISTANCE;
D O I
10.1177/2049936120901395
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Significant advances in the potency and tolerability of antiretroviral therapy (ART) have led to very high rates of virologic success for most who remain adherent to therapy. As a result, the life expectancy of people living with HIV (PLWH) has increased significantly. PLWH do, however, continue to experience a significantly higher risk of noninfectious comorbidities and chronic age-related complications, including cardiovascular disease and malignancies, which are now the biggest drivers of this excess morbidity and mortality. Therefore, in addition to virologic failure, the management of the treatment-experienced patient increasingly requires optimization of ART to enhance tolerability, avoid drug-drug interactions, and mitigate non-AIDS complications and comorbid conditions. This article will present principles of the management of virologic failure, poor immunologic recovery, and strategies for optimizing ART in the setting of virologic suppression.
引用
收藏
页数:15
相关论文
共 86 条
  • [1] Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial
    Aboud, Michael
    Kaplan, Richard
    Lombaard, Johannes
    Zhang, Fujie
    Hidalgo, Jose A.
    Mamedova, Elmira
    Losso, Marcelo H.
    Chetchotisakd, Ploenchan
    Brites, Carlos
    Sievers, Jorg
    Brown, Dannae
    Hopking, Judy
    Underwood, Mark
    Nascimento, Maria Claudia
    Punekar, Yogesh
    Gartland, Martin
    Smith, Kimberly
    [J]. LANCET INFECTIOUS DISEASES, 2019, 19 (03) : 253 - 264
  • [2] Abrams D, 2009, NEW ENGL J MED, V361, P1548, DOI 10.1056/NEJMoa0903175
  • [3] [Anonymous], 2006, PREZ DAR
  • [4] [Anonymous], 2013, TIVICAY DOL
  • [5] [Anonymous], 2019, TOP ANTIVIR MED
  • [6] [Anonymous], 2011, ED RILP
  • [7] [Anonymous], GUIDELINES USE ANTIR
  • [8] [Anonymous], 2015, PREZCOBIX DAR COB
  • [9] Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI
    Arribas, Jose R.
    DeJesus, Edwin
    van Lunzen, Jan
    Zurawski, Christine
    Doroana, Manuela
    Towner, William
    Lazzarin, Adriano
    Nelson, Mark
    McColl, Damian
    Andreatta, Kristen
    Swamy, Raji
    Szwarcberg, Javier
    Thai Nguyen
    [J]. HIV CLINICAL TRIALS, 2017, 18 (03): : 118 - 125
  • [10] Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
    Arribas, Jose R.
    Girard, Pierre-Marie
    Landman, Roland
    Pich, Judit
    Mallolas, Josep
    Martinez-Rebollar, Maria
    Zamora, Francisco X.
    Estrada, Vicente
    Crespo, Manuel
    Podzamczer, Daniel
    Portilla, Joaquin
    Dronda, Fernando
    Iribarren, Jose A.
    Domingo, Pere
    Pulido, Federico
    Montero, Marta
    Knobel, Hernando
    Cabie, Andre
    Weiss, Laurence
    Gatell, Jose M.
    [J]. LANCET INFECTIOUS DISEASES, 2015, 15 (07) : 785 - 792